Clinical features and treatment results in children with anaplastic large cell lymphoma

Anaplastic large cell lymphoma (ALCL) tends to have frequent relapse and good response to salvage chemotherapy. The frequency of ALCL among 1486 Non-Hodgkin's lymphoma (NHL) cases followed-up since 1972 was 1.5%, however, the percentage was 9.3% in cases diagnosed after 2000. Event-free survival (EFS) and overall survival (OS) rates for 23 children were 32.2% and 72.8% at 3 years, respectively. Disseminated diseases, no response to first line treatment, anaplastic lymphoma kinase (ALK) negativity were found as significant predictors on survival of ALCL. The proper diagnosis and early referral is essential in these children for a better survival rate. The children with ALK negative status should be monitored carefully because of the poor prognostic factors, and treated differently. The survival rates in this study are need of further improvement since the survival rates with current protocols are achievable at a level more than 80%. This is mainly related with late referral of those children with advanced disease.

___

1. Kutluk MT, Yeşilipek A. Turkish National Pediatric Cancer Registry 2002-2008 (Turkish Pediatric Oncology Group and Turkish Pediatric Hematology Society). J Clin Oncol 2013; 31.

2. Burkhardt B, Zimmermann M, Oschlies I, et al. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol 2005; 131: 39-49.

3. Jaffe E, Harris NL, Stein H, et al. Introduction and overview of the classification of the lymphoid neoplasms. In: Swerdlow S, Campo E, Harris NL, et al.(ed). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th ed) Lyon, France: International Agency for Research on Cancer; 2008: 157-166.

4. Mora J, Filippa DA, Thaler HT, Polyak T, Cranor ML, Wollner N. Large cell non-Hodgkin lymphoma of childhood: analysis of 78 consecutive patients enrolled in 2 consecutive protocols at the Memorial SloanKettering Cancer Center. Cancer 2000; 88: 186-197.

5. Smith MA, Seibel NL, Altekruse SF, et al. Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol 2010; 28: 2625-2634.

6. Williams DM, Hobson R, Imeson J, et al. Anaplastic large cell lymphoma in childhood: analysis of 72 patients treated on The United Kingdom Children's Cancer Study Group chemotherapy regimens. Br J Haematol 2002; 117: 812-820.

7. Lamant L, McCarthy K, d'Amore E, et al. Prognostic impact of morphologic and phenotypic features of childhood ALK-positive anaplastic large-cell lymphoma: results of the ALCL99 study. J Clin Oncol 2011; 29: 4669-4676.

8. Seidemann K, Tiemann M, Schrappe M, et al. Shortpulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 2001; 97: 3699-3706.

9. Murphy SB. Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults. Semin Oncol 1980; 7: 332-339.

10. Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc of Hematol Educ Program 2009: 523-531.

11. Bergeron C, Patte C, Leverger G, et al. Treatment of childhood lymphoblastic lymphomas. Results of the SFOP LMT 89 protocol. International Society of Pediatric Oncology SIOP XXIX Meeting, Istanbul, Turkey, September 23-27, 1997. Med Pediatr Oncol 1997; 29: 313-500.

12. A predictive model for aggressive non-Hodgkin's lymphoma. The international Non-Hodgkin's Lymphoma Prognostic Factors project. N Engl J Med 1993; 30: 987-994.

13. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Amer Statist Assn 1958; 53: 457-481.

14. Cox DR. Regression models and life tables. J R Stat Soc 1972; 34: 187-220.

15. Raetz E, Perkins S, Davenport V, Cairo MS. B large-cell lymphoma in children and adolescents. Cancer Treat Rev 2003; 29: 91-98.

16. Gross TG, Perkins SL. Malignant Non-Hodgkin lymphomas in children. In: Pizzo PA, Poplack DG (ed). Principles and Practice of Pediatric Oncology. (6th ed) Chepter 23. Philadelphia, PA 19103 USA: Lippincott Williams & Wilkins; 2011: 663-682.

17. Percy CL, Smith MA, Linet M, Ries LAG, Friedman DL. Lymphomas and reticuloendothelial neoplasms. In: Ries LAG, Smith MA, Gurney JG (ed) Cancer incidence and survival among children and adolescents United States SEER Program 1975-1995. Bethesda, MD: National Cancer Institute, SEER Program; 1999: 35-49.

18. Buyukpamukcu M. Non-Hodgkin's lymphomas. In: Voute T KC, Barret A (ed). Cancer in children (4th ed) Oxford, UK: Oxford University Press; 1998: 119-136.

19. Rosolen A, Pillon M, Garaventa A, et al. Anaplastic large cell lymphoma treated with a leukemia-like therapy: report of the Italian Association of Pediatric Hematology and Oncology (AIEOP) LNH-92 protocol. Cancer 2005; 104: 2133-2140.

20. Cairo MS, Sposto R, Hoover-Regan M, et al. Childhood and adolescent large-cell lymphoma (LCL): a review of the Children's Cancer Group experience. Am J Hematol 2003; 72: 53-63.

21. Attarbaschi A, Mann G, Rosolen A, et al. Limited stage I disease is not necessarily indicative of an excellent prognosis in childhood anaplastic large cell lymphoma. Blood 2011; 117: 5616-5619.

22. Link MP, Shuster JJ, Donaldson SS, Berard CW, Murphy SB. Treatment of children and young adults with earlystage non-Hodgkin's lymphoma. N Engl J Med 1997; 337: 1259-1266.

23. Laver JH, Kraveka JM, Hutchison RE, et al. Advancedstage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediatedose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial. J Clin Oncol 2005; 23: 541-547.24. Le Deley MC, Rosolen A, Williams DM, et al.

Vinblastine in children and adolescents with highrisk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial. J Clin Oncol 2010; 28: 3987-3993.

25. Le Deley MC, Reiter A, Williams D, et al. Prognostic factors in childhood anaplastic large cell lymphoma: results of a large European intergroup study. Blood 2008; 111: 1560-1566.

26. Reiter A, Schrappe M, Parwaresch R, et al. NonHodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Munster Group. J Clin Oncol 1995; 13: 359-372.

27. Oschlies I, Lisfeld J, Lamant L, et al. ALK-positive anaplastic large cell lymphoma limited to the skin: clinical, histopathological and molecular analysis of 6 pediatric cases- a report from the ALCL99 study. Haematologica 2013; 98: 50-56.

28. Brugieres L, Le Deley MC, Rosolen A, et al. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group. J Clin Oncol 2009; 27: 897-903.

29. Perkins SL, Pickering D, Lowe EJ. Childhood anaplastic large cell lymphoma has a high incidence of ALK gene rearrangement as determined by immunohistochemical staining and fluorescent in situ hybridisation: a genetic and pathological correlation. Br J Haematol 2005; 131: 624-627.

30. Lowe EJ, Sposto R, Perkins SL, et al. Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: final results of Children's Cancer Group Study 5941. Pediatr Blood Cancer 2009; 52: 335-339.

31. Brugieres L, Deley MC, Pacquement H, et al. CD30(+) anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood 1998; 92: 3591-3598.

32. Ribeiro RC, Steliarova-Foucher E, Magrath I, et al. Baseline status of paediatric oncology care in ten lowincome or mid-income countries receiving My Child Matters support: a descriptive study. Lancet Oncol 2008; 9: 721-729.

33. Wrobel G, Mauguen A, Rosolen A, et al. Safety assessment of intensive induction therapy in childhood anaplastic large cell lymphoma: report of the ALCL99 randomised trial. Pediatr Blood Cancer 2011; 56: 1071- 1077.

34. Patte C, Auperin A, Michon J, et al. The Societe Francaise d'Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 2001; 97: 3370-3379.

35. Savage KJ, Harris NL, Vose JM, et al. ALKanaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008; 111: 5496-5504.
Turkish Journal of Pediatrics-Cover
  • ISSN: 0041-4301
  • Yayın Aralığı: Yılda 6 Sayı
  • Başlangıç: 1958
  • Yayıncı: Hacettepe Üniversitesi Çocuk Sağlığı Enstitüsü Müdürlüğü
Sayıdaki Diğer Makaleler

Meriç Kaymak-Cihan1, Olcay Kandemir2, Klara Dalva3, Neriman Sarı4, Nilgün Kurucu4, İnci Ergürhan-İlhan4

İnci ERGÜRHAN-İLHAN, Klara DALVA, Olcay KANDEMİR, Meriç KAYMAK-CİHAN, Neriman SARI

Hypersensitivity pneumonia in a schoolchild admitted to the hospital's asthma clinic

Nesrin MOGULKOÇ, Hikmet Tekin NACAROĞLU, Hüdaver ALPER, Semiha BAHÇECİ-ERDEM, Güner ÖZÇELİK, Canan Şule ÜNSAL-KARKINER, Demet CAN

Pediatric tuberculosis in Turkey: a review of 8-years period in a tertiary care hospital

GÜLSÜM İCLAL BAYHAN, Gönül TANIR, Özge METİN, HÜLYA ŞİMŞEK, Türkan AYDIN-TEKE, Fatma Nur ÖZ, ZEYNEP GÖKÇE GAYRETLİ AYDIN

Development of a screening tool for children's growing pains: validation, reliability control and clinical evaluation

Maria VASİLOPOULOU, Anastasios SPATHİS, Nikos MYRİOKEFALİTAKİS, Foteni ZAFEROPOULOU, Ioanna PASPATİ, Maria TSOLİA

A rare hydrocephalus complication: cortical blindness

EMRE ÜNAL, RAHŞAN GÖÇMEN, AYŞE İLKSEN ÇOLPAK IŞIKAY, ÖZLEM TEKŞAM

Can Burkitt's Lymphoma and Hodgkin's Lymphoma occur in siblings simultaneously?

Meriç KAYMAK-CİHAN, Olcay KANDEMİR, Klara DALVA, Neriman SARI, İNCİ ERGÜRHAN İLHAN

Systemic onset juvenile idiopathic arthritis with macrophage activation syndrome and coronary artery dilatation misdiagnosed as Kawasaki disease

GONCA KESKİNDEMİRCİ, Nuray AKTAY AYAZ, Neslihan MELİKOĞLU, Helen BORNAUN, Çiğdem AYDOĞMUŞ, Esin ALDEMİR, Gönül AYDOĞAN

Prolonged pacifier usage in infancy does not cause eating behavior problem later

Elif Nursel ÖZMERT, Nurcan BULUR, Nazan KAYMAZ, Mustafa TEKİN, Şule YILDIRIM, Fatih Köksal BİNNETOĞLU, Mustafa KILIÇ, Naci TOPALOĞLU, Sibel CEVİZCİ

Total oxidant status, total antioxidant capacity and ischemia modified albumin levels in children with celiac disease

Ersin SAYAR, SEBAHAT ÖZDEM, Gülbahar UZUN, ALİ İŞLEK, Aygen YILMAZ, Reha ARTAN

Hypersensitivity pneumonia in a schoolchild admitted to the hospital's asthma clinic

Semiha BAHÇECİ ERDEM, HİKMET TEKİN NACAROĞLU, canan Şule ÜNsAl KArKıNer, Güner ÖZÇELİK, NESRİN MOĞULKOÇ BISHOP, Hüdaver ALPER, Demet CAN